Дэниел Левитин: Счастливое старение. Рекомендации нейробиолога о том, как жить долго и хорошо

Впоследствии сумма урегулирования была уменьшена до 2 миллионов долларов. Federal Trade Commission, “Lumosity to Pay $2 Million to Settle FTC Deceptive Advertising Charges for Its ‘Brain Training’ Program,” January 5, 2016, https://www.ftc.gov/news-events/press-releases/2016/01/lumosity-pay-2-million-settle-ftc-deceptive-advertising-charges.

E. L. Green, “BrainFunction Firm Backed by DeVos Misled in Ads,” The New York Times, June 27, 2018, p. B3.

D. J. Simons et al., “Do ‘BrainTraining’ Programs Work?” Psychological Science in the Public Interest 17, no. 3 (2016): 103–186.

Simons et al., “Do ‘Brain-Training’ Programs Work?”

Simons et al., “Do ‘Brain-Training’ Programs Work?”

A. Shimamura, Get SMART! Five Steps toward a Healthy Brain (Scotts Valley, CA: CreateSpace, 2017).

B. Carey, “A Memory Jolt Raises Hopes,” The New York Times, February 13, 2018, p. D1.

M. S. Gazzaniga, Human: The Science behind What Makes Your Brain Unique (New York: Harper Perennial, 2008). Я уже писал об этом в статье: D. J. Levitin, “Brain Candy,” The New York Times, August 22, 2008, p. BR9.

A. D. Mohamed, “Neuroethical Issues in Pharmacological Cognitive Enhancement,” Wiley Interdisciplinary Reviews: Cognitive Science 5, no. 5 (2014): 533–549; H. Maslen, N. Faulmüller, and J. Savulescu, “Pharmacological Cognitive Enhancement– How Neuroscientific Research Could Advance Ethical Debate,” Frontiers in Systems Neuroscience 8 (2014): 107.

Presidential Committee for the Study of Bioethical Issues, “Gray Matters: Topics at the Intersection of Neuroscience, Ethics, and Society,” March 2015, https://bioethicsarchive.georgetown.edu/pcsbi/sites/default/files/GrayMatter_V2_508.pdf.

A. L. Allen and N. K. Strand, “Cognitive Enhancement and Beyond: Recommendations from the Bioethics Commission,” Trends in Cognitive Sciences 19, no. 10 (2015): 549–551.

K. L. Cropsey et al., “Mixed-Amphetamine Salts Expectancies among College Students: Is Stimulant Induced Cognitive Enhancement a Placebo Effect?” Drug and Alcohol Dependence 178 (2017): 302–309.

M. J. Farah et al., “When We Enhance Cognition with Adderall, Do We Sacrifice Creativity? A Preliminary Study,” Psychopharmacology 202, nos. 1–3 (2009): 541–547.

P. Gerrard and R. Malcolm, “Mechanisms of Modafinil: A Review of Current Research,” Neuropsychiatric Disease and Treatment 3, no. 3 (2007): 349.

M. J. Farah, “The Unknowns of Cognitive Enhancement,” Science 350, no. 6259 (2015): 379–380.

R. M. Battleday and A.-K. Brem, “Modafinil for Cognitive Neuroenhancement in Healthy Non-Sleep-Deprived Subjects: A Systematic Review,” European Neuropsychopharmacology 25 (2015): 1865–1881.

A. D. Mohamed, “The Effects of Modafinil on Convergent and Divergent Thinking of Creativity: A Randomized Controlled Trial,” Journal of Creative Behavior 50, no. 4 (2014): 252–267.

A. D. Mohamed and C. R. Lewis, “Modafinil Increases the Latency of Response in the Hayling Sentence Completion Test in Healthy Volunteers: A Randomised Controlled Trial,” PLoS One 9, no. 11 (2014): e110639.

L. Bäckman et al., “The Correlative Triad among Aging, Dopamine, and Cognition: Current Status and Future Prospects,” Neuroscience and Biobehavioral Reviews 30, no. 6 (2006): 791–807.

T. E. Wilens et al., “Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature,” Journal of the American Academy of Child and Adolescent Psychiatry 47, no. 1 (2008): 21–31.

I. Smith, “Psychostimulants and Artistic, Musical, and Literary Creativity,” in The Neuropsychiatric Complications of Stimulant Abuse, International Review of Neurobiology, vol. 120, ed. P. Taba, A. Lees, and K. Sikk, pp. 301–326 (Waltham, MA: Academic Press, 2015); S. J. Heishman, B. A. Kleykamp, and E. G. Singleton, “Meta-Analysis of the Acute Effects of Nicotine and Smoking on Human Performance,” Psychopharmacology 210, no. 4 (2010): 453–469.

B. Hahn et al., “Nicotine Enhances Visuospatial Attention by Deactivating Areas of the Resting Brain Default Network,” Journal of Neuroscience 27, no. 13 (2007): 3477–3489.

J. A. Gandelman, P. Newhouse, and W. D. Taylor, “Nicotine and Networks: Potential for Enhancement of Mood and Cognition in Late-Life Depression,” Neuroscience and Biobehavioral Reviews 84 (2018): 289–298.

G. E. Barreto, A. Iarkov, and V. E. Moran, “Beneficial Effects of Nicotine, Cotinine and Its Metabolites as Potential Agents for Parkinson’s Disease,” Frontiers in Aging Neuroscience 6 (2015): 340; M. Kolahdouzan and M. J. Hamadeh, “The Neuroprotective Effects of Caffeine in Neurodegenerative Diseases,” CNS Neuroscience and Therapeutics 23, no. 4 (2017): 272–290.

D. Hurley, “Will a Nicotine Patch Make You Smarter?” Scientific American, February 9, 2014, https://www.scientificamerican.com/article/will-a-nicotine-patch-make-you-smarter-excerpt/.

J. A. Apud et al., “Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects,” Neuropsychopharmacology 32, no. 5 (2007): 1011.

N. Borges, “Tolcapone-Related Liver Dysfunction,” Drug Safety 26, no. 11 (2003): 743–747.

J. Micallef et al., “Antiparkinsonian Drug-Induced Sleepiness: A Double-Blind Placebo-Controlled Study of L-Dopa, Bromocriptine and Pramipexole in Healthy Subjects,” British Journal of Clinical Pharmacology 67, no. 3 (2009): 333–340; D. A. Pizzagalli et al., “Single Dose of a Dopamine Agonist Impairs Reinforcement Learning in Humans: Behavioral Evidence from a Laboratory-Based Measure of Reward Responsiveness,” Psychopharmacology 196, no. 2 (2008): 221–232.

Из личного общения с Дэйвом Гамильтоном 8 июня 2019 года.

A. Ströhle et al., “Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials,” American Journal of Geriatric Psychiatry 23, no. 12 (2015): 1234–1249; J. T. O’Brien et al., “Clinical Practice with Anti-Dementia Drugs: A Revised (Third) Consensus Statement from the British Association for Psychopharmacology,” Journal of Psychopharmacology 31, no. 2 (2017): 147–168.

B. M. Altevogt, M. Davis, and D. E. Pankevich, eds., Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary (Washington, DC: National Academies Press, 2011).

Из личного общения с Карлосом Квинтаной 21 мая 2018 года.